Skip to content
PDFS

PDF Solutions, Inc.

PDF Solutions, Inc. Q2 FY2025 earnings call

August 9, 2025 · fiscal period ended 2025-06

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2025-08-09

Management highlights

  • Achieved record revenue in Q2 and reaffirmed 21%-23% revenue growth guidance for the year. - Significant bookings in enterprise-wide solutions (secureWISE, Sapience, Exensio) and characterization infrastructure. - DFI: Installed and qualified Q1 shipped tools as subscription upgrades, anticipate shipping another 2 tools for additional revenue. - SecureWISE showed strong bookings, positioned as foundation layer of supply chain orchestration. - Analytics benefited from characterization deal, first full quarter of secureWISE revenues, new secureWISE deal, Sapience Manufacturing Hub booking, and Exensio renewals. - Gross margin at 76% in Q2, higher than long-term target; operating margin at 19% in Q2, expanding from prior periods.
View in transcript ↓

Segment performance

Total revenues for Q2 were a record $51.7 million, up 24% year-over-year and 8% sequentially. Analytics revenue was a record $48.8 million, up 28% year-over-year. Revenue contribution from Integrated Yield Ramp was $2.9 million compared to $3.5 million in the same quarter last year, driven by reduction in fixed fee. Backlog ended the quarter at $233 million. Gross margins for Q2 were 76%, and operating margin was 19%.

View in transcript ↓

Guidance

  • Reaffirmed revenue growth guidance of 21%-23% for the year. - Backlog grew during the quarter, ending at $233 million. - Gross margin for Q2 was 76%, and year-to-date gross margin is 76%, both higher than long-term targets. - Operating margin for Q2 was 19%, expanding from prior periods, with aim to reach 20% operating margin long-term.
View in transcript ↓

Risks

  • Forward-looking statements made, actual results could differ materially. Reference to Risk Factors section in PDF's annual report on Form 10-K for fiscal year ended December 31, 2024, and subsequent SEC filings for detailed risks.
View in transcript ↓

Q&A highlights

Q: Give more color on Sapience, including if it's a new customer and SAP connection.

A: It's an existing customer, first contracts with factory operations/IDMs. SAP was involved in initial discussions.

Q: Update on secureWISE acquisition integration and products.

A: Moving over systems, expect completion in September, training sales teams, integrating secureWISE with DEX for more secure data transmission.

Q: China exposure and disruption risk.

A: China is important, operations bifurcated since 2017, relatively insulated from short-term shocks by royalty/gain share payments from past deployments.

Q: Intel partnership status and outlook.

A: Intel is an important customer, outlook improving, technology provided by PDF increasingly important for Intel's manufacturing.

Q: SAP partnerships vs other partnerships.

A: Need to orchestrate enterprise for AI deployment, secureWISE and DEX important for data orchestration, partnership with Advantest continues.

Q: China revenue details and sustainability.

A: China revenue up due to volume shipments and CV deployments, expected to remain significant for trailing edge nodes.

Q: Exensio renewal landscape and expansion.

A: Anticipate expansions in second half with additional modules, guided analytics and AI for test as drivers.

Q: MLOps update.

A: Significant announcements on MLOps coming in next month, MLOps is a big piece of AI for test.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

August 9, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.